Children's Hospital Colorado
Select a category:

Showing 1-10 of 101
Other

Childhood Leukemia in Primary Care

Learn to recognize the clinical presentation of childhood leukemia, review the diagnostic workup, and explore current treatment approaches with practical guidance for pediatric providers.

Condition

Leukemia

Children's Hospital Colorado is at the forefront of treating pediatric leukemia. Learn more about signs, types, and symptoms of leukemia in children.

Other

Kaden: Sharing the Childhood Leukemia Journey

Kaden’s family shares his childhood leukemia journey to support other families. Learn what helped their family throughout their fight against cancer.

Other

Ethan and Kevin: Cousins Beat Leukemia

Learn about Cousins Kevin and Ethan, more than 20 years apart, who battled the same type of leukemia at Children’s Hospital Colorado. Today, they are cancer-free cousins, enjoying life.

Articles

MERIT Award Advances Acute Lymphoblastic Leukemia Research

Matt Witkowski, PhD, receives a prestigious NIH R37 grant to study why advanced leukemia treatments fail and how to improve outcomes for kids with relapsed pediatric cancer.

Articles

Predicting Relapse in Leukemia with Digital Droplet PCR

Our pediatric oncologist and hematologist Amanda Winters, MD, PhD, is working on a way to more reliably predict relapse in leukemia patients.

Provider's location(s)

Patient ratings

Patient ratings and reviews are not available Why?

Contact

(720)777-6740
Articles

How Leukemia Leverages Lipid Uptake Pathways to Evade CAR-T Therapy

Researchers are exploring why a common form of childhood Leukemia evades CAR-T cell therapy, leading to relapse.

Other

After a Pediatric Leukemia Diagnosis: Frequently Asked Questions

When a child is diagnosed with leukemia, families have a lot of questions. Here are some of their most common questions, and the answers, from our pediatric cancer team.

Articles

ALA-CART: A Breakthrough CAR-T Cell Therapy Against Resistant Leukemia

ALA-CART is a new CAR-T cell therapy developed by our researchers to enhance targeting and efficacy against relapsed leukemia in preclinical studies, and possibly other cancers.